ArticleBMC infectious diseases2021
Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis.The American journal of emergency medicine · 2022Pooled it
- Trends, Seasonality, and the Impact of COVID-19 on ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Initial Empirical Antibiotic Treatment in Patients with COVID-19 is Associated with Excess Adverse Drug Reactions without Clinical Benefit.Turkish journal of pharmaceutical sciences · 2025Article
- Impact of easing COVID-19 restrictions on antibiotic usage in Eastern China using wastewater-based epidemiology.Nature communications · 2024Article
- The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks.Infection and drug resistance · 2024Article
- The Impact of Early Antibiotic Use on Clinical Outcomes of Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis.Infection and drug resistance · 2024Article
- Antimicrobial prescribing in a secondary care setting during the COVID-19 pandemic.JAC-antimicrobial resistance · 2023Article
- Antibiotics Prescriptions Pattern among Patients Visiting Primary Health Care Centers (PHCC) before and during COVID-19 Pandemic: A Cross-Sectional Population-Based Study from Qatar.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Stewardship in COVID-19 Patients: Those Who Sow Will Reap Even through Hard Times.Antibiotics (Basel, Switzerland) · 2023Article
- Pharmacist-driven antimicrobial stewardship interventions in patients with COVID-19: a scoping review.International journal of clinical pharmacy · 2023Article
- Hospital Antibiotic Use during COVID-19 Pandemic in Italy.Antibiotics (Basel, Switzerland) · 2023Article
- A multimodal antimicrobial stewardship intervention to improve antibiotic prescribing in patients with COVID-19.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Using a 29-mRNA Host Response Classifier To Detect Bacterial Coinfections and Predict Outcomes in COVID-19 Patients Presenting to the Emergency Department.Microbiology spectrum · 2022Article
- Clinical Characteristics and Management of Patients with a Suspected COVID-19 Infection in Emergency Departments: A European Retrospective Multicenter Study.Journal of personalized medicine · 2022Article
- SHEA statement on antibiotic stewardship in hospitals during public health emergencies.Infection control and hospital epidemiology · 2022Article
- Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey.Pathogens and global health · 2022Article
- Pneumomediastinum and Pneumopericardium as Uncommon Complications of COVID-19 Infection: A Review Article.Cureus · 2022Review
- The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- To Prescribe, or Not to Prescribe, That Is the Question.Journal of Korean medical science · 2022Article
- Antibiotic Use and Bacterial Infection in COVID-19 Patients in the Second Phase of the SARS-CoV-2 Pandemic: A Scoping Review.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEmpiric antibiotics for community acquired bacterial pneumonia (CABP) are often prescribed to patients with COVID-19, despite a low reported incidence of co-infections. Stewardship interventions targeted at facilitating appropriate antibiotic prescribing for CABP among COVID-19 patients are needed. We developed a guideline for antibiotic initiation and discontinuation for CABP in COVID-19 patients. The purpose of this study was to assess the impact of this intervention on the duration of empiric CABP antibiotic therapy among patients with COVID-19.
methodsThis was a single-center, retrospective, quasi-experimental study of adult patients admitted between 3/1/2020 to 4/25/2020 with COVID-19 pneumonia, who were initiated on empiric CABP antibiotics. Patients were excluded if they were initiated on antibiotics > 48 h following admission or if another source of infection was identified. The primary outcome was the duration of antibiotic therapy (DOT) prior to the guideline (March 1 to March27, 2020) and after guideline implementation (March 28 to April 25, 2020). We also evaluated the clinical outcomes (mortality, readmissions, length of stay) among those initiated on empiric CABP antibiotics.
resultsA total of 506 patients with COVID-19 were evaluated, 102 pre-intervention and 404 post-intervention. Prior to the intervention, 74.5% (n = 76) of patients with COVID-19 received empiric antibiotics compared to only 42% of patients post-intervention (n = 170), p < 0.001. The median DOT in the post-intervention group was 1.3 days shorter (p < 0.001) than the pre-intervention group, and antibiotics directed at atypical bacteria DOT was reduced by 2.8 days (p < 0.001). More patients in the post-intervention group were initiated on antibiotics based on criteria consistent with our guideline (68% versus 87%, p = 0.001). There were no differences between groups in terms of clinical outcomes.
conclusionFollowing the implementation of a guideline outlining recommendations for initiating and discontinuing antibiotics for CABP among COVID-19 inpatients, we observed a reduction in antibiotic prescribing and DOT. The guideline also resulted in a significant increase in the rate of guideline-congruent empiric antibiotic initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.